PHS
CAPR icon

PFM Health Sciences’s Capricor Therapeutics CAPR Stock Holding History

PFM Health Sciences’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.76M Buy
+123,831
New +$3.3M 0.34% 70
2025
Q2 		– Sell
-140,681
Closed -$1.34M – 62
2025
Q1 		$1.34M Buy
140,681
+86,324
+159% +$1.2M 0.1% 55
2024
Q4 		$750K Sell
54,357
-98,422
-64% -$1.72M 0.05% 79
2024
Q3 		$2.32M Buy
+152,779
New +$756K 0.13% 64

Other funds holding CAPR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

PFM Health Sciences's CAPR Position: Q1 2026 in Review

PFM Health Sciences opened a new position in Capricor Therapeutics (CAPR) in Q1 2026: 123,831 shares worth $3.76M. The stake represents 0.34% of the portfolio and ranks #70 among its holdings. This is a return to the name: PFM Health Sciences previously reported a position in CAPR as recently as Q1 2025.

PFM Health Sciences first reported a position in CAPR in Q3 2024 and has held it in 4 quarters since. 177 funds tracked by Wall St. Rank hold CAPR as of Q1 2026.

  • PFM Health Sciences held 123,831 shares of Capricor Therapeutics worth $3.76M as of Q1 2026.
  • Capricor Therapeutics was a new PFM Health Sciences position in Q1 2026.
  • Capricor Therapeutics made up 0.34% of PFM Health Sciences's portfolio in Q1 2026, its #70 holding.
  • PFM Health Sciences first reported a position in Capricor Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • 177 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2026.

Based on PFM Health Sciences's 13F filing for Q1 2026, filed 15 May 2026.